DOI: 10.1007/s00259-017-3695-3Pages: 41-54

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

1. Medical Oncology Princess Margaret Cancer Centre, Drug Development Program

2. Normandie Univ, UNICAEN, Inserm, ANTICIPE (Interdisciplinary Research for Cancers Prevention and Treatment, axis 2 BioTICLA (Biology and Innovative Therapeutics for Locally Aggressive Cancers)

3. UNICANCER, Comprehensive Cancer Center Fran├žois Baclesse

4. Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University of Toronto, Department of Medical Biophysics, Department of Immunology

5. The Institute of Cancer Research & The Royal Marsden NHS Trust, Drug Development Unit

6. Maastricht University Medical Centre (MUMC+), Department of Radiology and Nuclear Medicine

7. University Hospital, RWTH Aachen University, Department of Nuclear Medicine

Correspondence to:
F. M. Mottaghy



Molecular imaging continues to influence every aspect of cancer care including detection, diagnosis, staging and therapy response assessment. Recent advances in the understanding of cancer biology have prompted the introduction of new targeted therapy approaches. Precision medicine in oncology has led to rapid advances and novel approaches optimizing the use of imaging modalities in cancer care, research and development. This article focuses on the concept of targeted therapy in cancer and the challenges that exist for molecular imaging in cancer care.

This article is freely available, click here to access the full text/PDF

  • Accepted: Mar 27, 2017
  • Online: Apr 10, 2017

Article Tools